Halozyme Reports First Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Halozyme Therapeutics (HALO) Tops Q1 EPS by 3c
May 10, 2018 4:28 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of ($0.19), $0.03 better than the analyst estimate of ($0.22). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $31.43 million.
GUIDANCE:
Halozyme Therapeutics sees FY2018 revenue of $115-125 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
... More